Drug General Information
Drug ID
D0U7IL
Former ID
DNCL002882
Drug Name
LX-4211
Drug Type
Small molecular drug
Indication Type 2 diabetes [ICD9: 250; ICD10:E11] Phase 2 [524151], [543064]
Company
Lexicon Pharmaceuticals
Structure
Download
2D MOL
Formula
C21H25ClO5S
InChI
InChI=1S/C21H25ClO5S/c1-3-26-15-7-4-12(5-8-15)10-14-11-13(6-9-16(14)22)20-18(24)17(23)19(25)21(27-20)28-2/h4-9,11,17-21,23-25H,3,10H2,1-2H3/t17-,18-,19+,20+,21-/m1/s1
InChIKey
QKDRXGFQVGOQKS-CRSSMBPESA-N
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) Sodium/glucose cotransporter 1 Target Info Modulator [531953]
SLGT2 Target Info Modulator [531953]
KEGG Pathway Carbohydrate digestion and absorption
Bile secretion
Mineral absorption
PathWhiz Pathway Lactose Degradation
Trehalose Degradation
Reactome Hexose transport
Na+-dependent glucose transporters
Inositol transportersR-HSA-189200:Hexose transport
Inositol transporters
WikiPathways NRF2 pathway
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds
Metabolism of carbohydratesWP2884:NRF2 pathway
Nuclear Receptors Meta-Pathway
References
Ref 524151ClinicalTrials.gov (NCT01742208) Safety and Efficacy of LX4211 in Patients With Inadequately Controlled Type 1 Diabetes Mellitus. U.S. National Institutes of Health.
Ref 543064(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8312).
Ref 531953LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther. 2012 Aug;92(2):158-69.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.